FDA and EMA Release Joint Guiding Principles for Good AI Practice in Drug Development
On January 14, 2026, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) jointly published a set of 10 guiding principles for the responsible, effective, and trustworthy use of artificial intelligence (AI) across the entire drug product life cycle — from early discovery through post-marketing pharmacovigilance. The announcement, distributed through official…
